Ephedrine
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Ephedrine: From Decongestant/Vasopressor Use to Nasal Cavity Disease
One-Sentence Summary
Ephedrine is a sympathomimetic (α/β-adrenergic agonist) historically used as a nasal decongestant and as a vasopressor for anesthesia-related hypotension, though no Taiwan-approved indication is currently on file for this drug. The TxGNN model predicts it may be effective for Nasal Cavity Disease, a finding that is mechanistically plausible but currently supported mainly by indirect, class-level evidence — 18 clinical trials (mostly non-ephedrine-specific) and 8 publications were retrieved, with only a handful directly relevant.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in Taiwan license data (no TFDA license on file); historically used as a nasal decongestant/vasopressor per drug class |
| Predicted New Indication | Nasal Cavity Disease |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L3 |
| Market Status (Taiwan) | 未上市 (Not Marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack (original_moa: Data Gap). Based on the drug class and the repurposing rationale attached to this candidate, ephedrine is an indirect-acting α/β-adrenergic agonist that produces vasoconstriction in nasal mucosal blood vessels, reducing mucosal congestion and swelling — the classic “decongestant” mechanism. This is a well-established pharmacological property rather than a speculative link.
Because ephedrine has historically been used in nasal decongestant preparations, the predicted association with Nasal Cavity Disease largely represents reconfirmation of an already-known pharmacological use rather than a genuinely novel mechanistic hypothesis. However, since this evidence pack records no formal original indication and no Taiwan licensing history, the prediction still needs to be substantiated with drug-specific (not merely drug-class) clinical evidence before it can be treated as validated.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00562120 | Phase 2 | Completed | 21 | Randomized, double-blind, double-dummy, crossover study of an H3-receptor antagonist on nasal congestion after allergen challenge in seasonal allergic rhinitis; methodologically rigorous decongestant-comparison model, but ephedrine is not explicitly confirmed as a study arm |
| NCT01886768 | N/A | Unknown | 212 | Compared double- vs single-pledget nasal anesthesia for transnasal endoscopy; ephedrine-soaked pledgets are commonly used clinically for pre-procedural mucosal vasoconstriction |
| NCT00939393 | N/A | Completed | 72 | Endoscopic sinus surgery performed in-office vs. operating room; topical vasoconstrictors (including ephedrine-class agents) are routinely used to reduce intraoperative bleeding, but the trial itself compares care setting, not the drug |
| NCT05131958 | N/A | Unknown | 30 | Multiparametric (imaging/aerodynamic/acoustic) evaluation of nasality in nasal polyposis; observational, no drug intervention |
| NCT06457100 | Phase 1/2 | Active, not recruiting | 60 | Compares esmolol vs. lidocaine infusion for recovery quality after functional endoscopic sinus surgery; unrelated to ephedrine |
| NCT01854619 | N/A | Unknown | 48 | Photodynamic disinfection for chronic rhinosinusitis; non-pharmacologic mechanism |
| NCT06580210 | N/A | Recruiting | 114 | Mechanical decongestant seawater spray with essential oils for acute rhinitis; medical device, not a drug study |
| NCT04048174 | N/A | Completed | 27 | Probiotic bacteria (L. lactis) instilled into nasal/sinus cavities for chronic rhinosinusitis; unrelated mechanism |
| NCT05494346 | N/A | Recruiting | 101 | Decongestant seawater spray pocket valve with essential oils; medical device performance/safety study |
| NCT00015795 | Phase 1 | Completed | 30 | Laryngeal airflow resistance in abductor spasmodic dysphonia; indication unrelated to nasal cavity congestion |
None of the retrieved trials directly evaluate ephedrine as the study drug for a nasal-cavity indication; relevance is largely inferred from procedural context (e.g., ephedrine’s known off-label use as a nasal vasoconstrictor during ENT procedures).
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 14211229 | 1964 | RCT (early era) | Svenska läkartidningen | Early experimental clinical testing of N-hydroxyethylpromethazine chloride combined with ephedrine hydrochloride applied in the nasal cavity |
| 11345158 | 2001 | Comparative/Cohort | American Journal of Rhinology | Compared oral/topical decongestant effects of phenylpropanolamine and d-pseudoephedrine (related sympathomimetic class, not ephedrine itself) using acoustic rhinometry |
| 1541887 | 1992 | Comparative clinical study | The Journal of Laryngology and Otology | Compared nasal packing vs. spraying for pre-operative nasal preparation |
| 8283338 | 1993 | Case series | Nihon Jibiinkoka Gakkai Kaiho | Case series of congenital nasal stenosis, treated with nasal or oral intervention |
| 11789239 | 2000 | Clinical observation (uncontrolled) | Chinese Journal of Integrated Traditional and Western Medicine | Uncontrolled clinical observation of a rhinitis spray for chronic rhinitis |
| 12962193 | 2003 | Animal model (pharmacology) | American Journal of Rhinology | Dog model of allergic nasal congestion using acoustic rhinometry |
| 12387934 | 2002 | Animal model (pharmacology) | Journal of Pharmacological and Toxicological Methods | Pharmacological characterization of a chronic dog model of nasal congestion for studying decongestant mechanisms |
| 11895194 | 2002 | Animal model (pharmacology) | American Journal of Rhinology | Acoustic rhinometry in dogs as a large-animal model of nasal congestion |
Evidence is weighted toward animal pharmacology models and older/uncontrolled clinical observations; only one early-era (1964) study directly names ephedrine in a nasal-cavity clinical context.
US Market Information
Ephedrine currently holds no marketing authorization license in Taiwan (0 NDAs on file; market status: not marketed).
Safety Considerations
Please refer to the package insert for safety information.
(Note: key_warnings, contraindications, and DDI data are all marked as data gaps in this evidence pack — including a Blocking-severity gap for TFDA label warnings/contraindications, which prevents a formal S1 safety pre-assessment.)
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence level is L3 (observational/indirect only) with no clinical trial directly confirming ephedrine’s efficacy in nasal cavity disease, and a Blocking-severity data gap (missing TFDA label warnings/contraindications) prevents entry into the S1 safety pre-assessment stage. Ephedrine also has no current Taiwan marketing license, further limiting near-term actionability.
To proceed, the following is needed:
- TFDA label warnings/contraindications (DG001, Blocking) — required before any safety pre-assessment
- Confirmed mechanism of action from DrugBank (DG002)
- Drug-specific (not decongestant-class) clinical trials evaluating ephedrine for nasal cavity disease
- Assessment of Taiwan regulatory pathway, given the drug is currently unmarketed (0 licenses)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.